ATHIRA PHARMA INC (ATHA)

Company Profile

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 63 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and stop neurodegeneration. Its pipeline consists of both blood brain barrier (BBB) permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system (PNS), and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. The company is also advancing potential drug candidates for neuropathic pain, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. Its neuropathic pain drug candidate, ATH-1020, completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.

Company Info

ATHIRA PHARMA INC

18706 North Creek Parkway, Suite 104, Box 352141

Bothell WASHINGTON 98011

P: 14256208501

CEO: Leen Kawas

Employees: 63

Website: https://www.athira.com/